12:00 AM
May 16, 2016
 |  BC Week In Review  |  Company News  |  Other News

Epirus biosimilars, hematology, cancer news

Epirus will reduce headcount by 40% to reprioritize its pipeline to focus exclusively on developing biosimilars for rare diseases. The company will suspend development of its Phase III-ready lead program BOW015, a biosimilar of Remicade infliximab, and reallocate resources to develop...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >